SOURCE: Aradigm Corp.

March 23, 2007 12:13 ET

Aradigm to Hold 2006 Fourth Quarter Financial Results Conference Call March 29

HAYWARD, CA -- (MARKET WIRE) -- March 23, 2007 -- Aradigm Corporation (OTCBB: ARDM), a specialty pharmaceutical company, will release its 2006 fourth quarter and year end financial results after the market close on Thursday, March 29, 2007.

Aradigm's President and Chief Executive Officer Igor Gonda, Ph.D., and Company management will be hosting an investment-community conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Thursday, March 29, 2007 to discuss the financial results, provide a business update and to answer questions.

To participate in the live call by telephone, please dial (800) 323-0845 from the U.S., and for international callers, please dial (706) 634-8407. A telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 3488287.

Individuals interested in listening to the conference call via the Internet may do so by visiting An archived presentation will be available on the Web site for 14 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary hypertension, inhalation anthrax infections and smoking cessation.

In addition, Aradigm's AERx insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. More information about Aradigm can be found at

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-K, and quarterly reports on Form 10-Q.

Aradigm and AERx are registered trademarks of Aradigm.

Contact Information

  • Contact:

    Investor Relations
    (510) 265-8850/6565

    Lippert/Heilshorn & Associates
    Don Markley or Bruce Voss
    (310) 691-7100